In Week of Mar 28, 2026, Zydus Lifesciences Ltd (Pharma - Formulators) is outperforming Nifty 500 with +10.0% relative strength. Fundamentals: Weak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 14, 2026
What: Filing for Primary Biliary Cholangitis indication expected in Q4 FY26
Impact: +₹500 Cr revenue
“Management plans to file Saroglitazar Magnesium with USFDA for PBC indication as pivotal specialty pharma growth milestone”
What: First FDA-approved therapy for Menkes disease launched
Impact: +₹200 Cr revenue
“Received final USFDA approval for Zycubo in January 2026 as first and only Menkes disease therapy”
What: Pembrolizumab and Ranibizumab biosimilars development
Impact: +₹1000 Cr revenue
“Strategic biosimilar partnerships discussed for high-value oncology and ophthalmology products”
Earnings deceleration risks from management commentary
Trigger: New Labour Codes implementation
Impact: -200 bps margin impact
Management view: Exceptional items totaling ₹849 million primarily from New Labour Codes implementation impact
Monitor: Exceptional expenses in next quarter
Trigger: Lenalidomide market dynamics
Impact: -150 bps margin impact
Management view: Q4 EBITDA margins expected at 23% plus despite minimal Lenalidomide revenue
Monitor: US generics segment growth rate
Key quotes from recent conference calls
“The company plans to file Saroglitazar Magnesium with the USFDA for PBC indication, marking a pivotal milestone for growth in the specialty pharmaceutical space. — Dr. Sharvil Patel”
“In January 2026, the company received final approval from the USFDA for Zycubo (copper histidinate), becoming the first and only therapy approved for the treatment of Menkes disease. — Earnings Call Transcript”
“R&D, as I said, we expect a 7.5%-8% of our revenue for FY26. — Dr. Sharvil Patel”
“Management expressed confidence in continued double-digit growth across key business segments, with the US generics business showing 11% volume growth and international markets expected to maintain 20% plus growth trajectory. — Earnings Call Transcript”
Forward-looking targets from management for Next 2-4 quarters
Revenue Growth Target
10%
Implied PAT Growth
5%
OPM Guidance
23%
Key Milestones
• Saroglitazar PBC filing in Q4 FY26
• Zycubo commercialization
• Biosimilar partnerships progression
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +30% | +15% | Stable |
| PAT (Net Profit) | 0% | +0% | Stable |
| OPM | 26.0% | 0 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 14, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Zydus Lifesciences Ltd's latest quarterly results (Dec 2025) show
Zydus Lifesciences Ltd's profit is declining with an stable trend.
Zydus Lifesciences Ltd's revenue growth trend is stable.
Zydus Lifesciences Ltd's operating margin is volatile.
Zydus Lifesciences Ltd's long-term compounding rates
Zydus Lifesciences Ltd's earnings growth is stable with mixed signals on a sequential basis.
Zydus Lifesciences Ltd's trailing twelve month (TTM) performance
Zydus Lifesciences Ltd appears fairly valued based on our fair value analysis.
Zydus Lifesciences Ltd's current PE ratio is 17.7x.
Zydus Lifesciences Ltd's current PE is 17.7x.
Zydus Lifesciences Ltd's price-to-book ratio is 3.6x.
Zydus Lifesciences Ltd is rated Weak with a fundamental score of 38.61/100. This score is calculated from objective financial metrics
Zydus Lifesciences Ltd has a debt-to-equity ratio of N/A.
Zydus Lifesciences Ltd's return ratios over recent years
Zydus Lifesciences Ltd's operating cash flow is positive (FY2025).
Zydus Lifesciences Ltd's current dividend yield is 1.23%.
Zydus Lifesciences Ltd's shareholding pattern (Dec 2025)
Zydus Lifesciences Ltd's promoter holding has remained stable recently.
Zydus Lifesciences Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.
Zydus Lifesciences Ltd is an established outperformer with 3 weeks of consecutive Nifty 500 outperformance.
Zydus Lifesciences Ltd has 3 key growth catalysts identified from recent earnings analysis
Zydus Lifesciences Ltd has 2 key risks worth monitoring
In Q3 FY26, Zydus Lifesciences Ltd's management highlighted
Zydus Lifesciences Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Zydus Lifesciences Ltd may be worth studying
Zydus Lifesciences Ltd investment thesis summary:
Zydus Lifesciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
